Mitochondrial Structure and Function Adaptation in Residual Triple Negative Breast Cancer Cells Surviving Chemotherapy Treatment

Authors

Mokryun L Baek
Junegoo Lee
Katherine E Pendleton
Mariah J Berner
Emily B Goff
Lin Tan
Sara A Martinez
Iqbal Mahmud
Tao Wang
Matthew D Meyer
Bora Lim
James P Barrish
Weston Porter
Philip L Lorenzi
Gloria V Echeverria

Publication Date

3-1-2023

Journal

Oncogene

Abstract

Neoadjuvant chemotherapy (NACT) used for triple negative breast cancer (TNBC) eradicates tumors in ~45% of patients. Unfortunately, TNBC patients with substantial residual cancer burden have poor metastasis free and overall survival rates. We previously demonstrated mitochondrial oxidative phosphorylation (OXPHOS) was elevated and was a unique therapeutic dependency of residual TNBC cells surviving NACT. We sought to investigate the mechanism underlying this enhanced reliance on mitochondrial metabolism. Mitochondria are morphologically plastic organelles that cycle between fission and fusion to maintain mitochondrial integrity and metabolic homeostasis. The functional impact of mitochondrial structure on metabolic output is highly context dependent. Several chemotherapy agents are conventionally used for neoadjuvant treatment of TNBC patients. Upon comparing mitochondrial effects of conventional chemotherapies, we found that DNA-damaging agents increased mitochondrial elongation, mitochondrial content, flux of glucose through the TCA cycle, and OXPHOS, whereas taxanes instead decreased mitochondrial elongation and OXPHOS. The mitochondrial effects of DNA-damaging chemotherapies were dependent on the mitochondrial inner membrane fusion protein optic atrophy 1 (OPA1). Further, we observed heightened OXPHOS, OPA1 protein levels, and mitochondrial elongation in an orthotopic patient-derived xenograft (PDX) model of residual TNBC. Pharmacologic or genetic disruption of mitochondrial fusion and fission resulted in decreased or increased OXPHOS, respectively, revealing longer mitochondria favor oxphos in TNBC cells. Using TNBC cell lines and an in vivo PDX model of residual TNBC, we found that sequential treatment with DNA-damaging chemotherapy, thus inducing mitochondrial fusion and OXPHOS, followed by MYLS22, a specific inhibitor of OPA1, was able to suppress mitochondrial fusion and OXPHOS and significantly inhibit regrowth of residual tumor cells. Our data suggest that TNBC mitochondria can optimize OXPHOS through OPA1-mediated mitochondrial fusion. These findings may provide an opportunity to overcome mitochondrial adaptations of chemoresistant TNBC.

Keywords

Humans, Triple Negative Breast Neoplasms, Cell Line, Tumor, Antineoplastic Agents, Mitochondria, Oxidative Phosphorylation

DOI

10.1038/s41388-023-02596-8

PMID

36813854

PMCID

PMC10069007

PubMedCentral® Posted Date

4-3-2023

PubMedCentral® Full Text Version

Author MSS

Published Open-Access

yes